Impact of a community pharmacy based information program on type 2 diabetic patients' adherence to their oral treatment

Submission date	Recruitment status No longer recruiting	Prospectively registered	
03/03/2017		[_] Protocol	
Registration date	Overall study status	[] Statistical analysis plan	
25/04/2017	Completed	[X] Results	
Last Edited 01/05/2020	Condition category Nutritional, Metabolic, Endocrine	[] Individual participant data	

Plain English summary of protocol

Background and study aims

Diabetes is a lifelong (chronic) condition that causes a person's blood sugar level to become too high. A survey found that although 80% of patients with type 2 diabetes say they are well informed, 71% would like other additional information. Only 17% of the same patients report receiving instruction in addition to their treatment. Pharmacists could exert a major effect on treatment adherence in chronic disease. The aim of this study to assess the impact of information provided by community pharmacists on patients' adherence to treatment.

Who can participate? Patients aged over 18 with type 2 diabetes

What does the study involve?

Participants are randomly allocated to one of two groups. Participants in one group attend interviews with a pharmacist three times over 6 months (once every 2 months) covering diet, drug treatment and the complications of diabetes. Each interview lasts about thirty minutes and involves general monitoring of the patient and then giving the patient a brochure which is an opening for a discussion between the pharmacist and the patient. Participants in the other group receive treatment as usual. The impact on treatment adherence is assessed in both groups after 6 months by the pharmacist counting the tablets remaining in the treatment packs delivered to the patient during the previous visit.

What are the possible benefits and risks of participating? The benefits for the patient are a better knowledge of diet and the complications of diabetes, as well as better management of their treatment. There are no expected risks for the participants.

Where is the study run from? 182 pharmacies in France

When is the study starting and how long is it expected to run for? March 2014 to December 2016 Who is funding the study? Merck (USA)

Who is the main contact? Dr Yves Michiels

Contact information

Type(s) Scientific

Contact name Dr Yves Michiels

Contact details 1 rue Guynemer Longvic France 21600

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 012014

Study information

Scientific Title

Impact of a community pharmacy based information program on type 2 diabetic patients' adherence to their oral treatment (IPhODia): a randomized cluster study vs usual practice

Acronym IPhODia

Study objectives

Diabetes is a prime example of a chronic disease which is increasingly prevalent in France (38% in 7 years) and accounts for nearly 10% of our health spending. The many complications associated with diabetes contribute substantially to this spending and occur when diabetes is insufficiently controlled. The current therapeutic objective of the treatment is measured by the level of Hba1C which should be < 7% as defined by NHANES.

In France, despite significant improvements in the follow up of type 2 diabetes patients, the last results of Entred 2007-2010 are showing an insufficient level of control with too many patients with HbA1C>7%. This epidemiological study points to improved control of cardiovascular risk

factors (lipid profile, high blood pressure) but still inadequate control of glycaemia. Some 41% of people with type 2 diabetes have HbA1c levels above 7% and 15% have levels above 8%.

These figures, testifying to failed therapy, are the source of many hospitalizations especially as glycaemic balance is not achieved. Alongside this, the costs of cover are proportional to this absence of control. The annual cost of a diabetic patient rises from \$2 792 for an HbA1c < 7% to \$6 759 for an HbA1c of 10%. Several additional measures should be contemplated to make therapy more efficacious. Adherence or rather non-adherence is inherent in chronic drug treatment and for diabetes, many studies are increasingly highlighting adherence as a factor for successful or unsuccessful drug treatment. Adherence seems to be one of the key points for the successful treatment of a chronic diseases like diabetes.

General practitioners remain the prime point-of-contact for diabetic patients, in spite of regular controls, physicians encounter difficulties correctly informing their patients mainly due to a lack of time and means. Diabetic patients must, in the majority (90%) of cases, go to the pharmacy for their treatment to be renewed and dispensed. This should be a useful opportunity for detecting and correcting any decline in adherence. Pharmacists, who are par excellence specialists in medication, are an essential actor and thanks to their expertise, their large number and their accessibility, pharmacists could play a beneficial role in patient adherence.

The IPhODia study aims to assess the impact on adherence of specific information provided by community pharmacists.

Ethics approval required Old ethics approval format

Ethics approval(s) In France a clinical trial such as IPhODia does not require ethics approval

Study design Prospective multicentre randomised controlled trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Community

Study type(s) Other

Participant information sheet Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied Diabetes

Interventions

The intervention consists of three different pharmaceutical interviews during 6 months (one every 2 months) covering thematic information on diabetes, namely diet for diabetics, monitoring drug treatment and the complications of diabetes. Each interview is composed of two parts and lasts about 30 minutes. It involves first general monitoring of the diabetic patient and then giving the patient a thematic information brochure which is an opening for a discussion between the pharmacist and the patient.

In order to demonstrate the effectiveness of this intervention, a randomised study is performed with two groups of patients, one receiving information from the pharmacists according to the program, the other receiving treatment as usual. Impact on adherence will be assessed using the Medication Possession Ratio (MPR) at 6 months.

Intervention Type

Other

Primary outcome measure

Medication Possession Ratio (MPR), measured by the pharmacist by counting tablets remaining in the treatment packs delivered to the patient during the previous visit, at 6 months

Secondary outcome measures

1. HbA1c level, measured by laboratory analysis at 6 months

2. Adherence, measured by a specific questionnaire (TOP) at 6 months

3. Patient's knowledge acquisition, measured by a specific questionnaire developed by the scientific committee at 6 months

4. Patient's satisfaction, measured by a specific questionnaire developed by the scientific committee, for the patients in group A at 6 months

Overall study start date

01/03/2014

Completion date

31/12/2016

Eligibility

Key inclusion criteria

- 1. Men or women
- 2. Age >18 years
- 3. Diabetics with less four oral antidiabetics medications
- 4. HbA1c> 6.7%
- 5. Patient present at pharmacy for more than 6 months

Participant type(s) Patient

Age group Adult

Lower age limit

18 Years

Sex Both

Target number of participants 800

Key exclusion criteria 1. Cancer 2. Patients with insulin treatment or anti-diabetics injectables

Date of first enrolment 01/03/2014

Date of final enrolment 01/09/2016

Locations

Countries of recruitment France

Study participating centre PHARMACIE NGHIEM France 91600

Study participating centre PHARMACIE BONNET France 34000

Study participating centre PHARMACIE GOULET France 76620

Study participating centre PHARMACIE SUEUR France 80230 **Study participating centre PHARMACIE HENRY** France 18120

Study participating centre PHARMACIE BOUDON France 15120

Study participating centre PHARMACIE BERTHOLOM France 29910

Study participating centre PHARMACIE LAIR-MARTIN-LONGUESSERRE France 31260

Study participating centre PHARMACIE STAHL France 88290

Study participating centre PHARMACIE BERTOUX-FORESTIER France 80134

Study participating centre PHARMACIE BERA France 38114 Study participating centre PHARMACIE DERAM France

62220

Study participating centre PHARMACIE RENUCCI France 84210

Study participating centre PHARMACIE SCHAUB France 73230

Study participating centre PHARMACIE GERMES-CANEPA France 35300

Study participating centre PHARMACIE LOUBRIEU France 49240

Study participating centre PHARMACIE OSTER-HILD France 67400

Study participating centre PHARMACIE LAFORTUNE France 91390

PHARMACIE BIZON France 49280

Study participating centre PHARMACIE VAURY France 91670

Study participating centre PHARMACIE THOUVEREY France 71500

Study participating centre PHARMACIE MINGEAU France 58150

Study participating centre PHARMACIE BOUTINET-DJILANI France 17650

Study participating centre PHARMACIE VITOUX-GILLET France 59550

Study participating centre PHARMACIE MOUTIER-DUMAS France 87130

PHARMACIE LEPINE France 87220

Study participating centre PHARMACIE DRIOUT France 41500

Study participating centre PHARMACIE TROUSSELLE France 49000

Study participating centre PHARMACIE TARODO DE LA FUENTE France 81240

Study participating centre PHARMACIE RAYMOND-TAUGOURDEAU France 49112

Study participating centre PHARMACIE BEGLIA JOEL France 13200

Study participating centre PHARMACIE SCHAUB France 73230

PHARMACIE BREYSSE France 81200

Study participating centre PHARMACIE MALLIS France 62440

Study participating centre PHARMACIE BONCHRISTIANI-ANDREANI France 13013

Study participating centre PHARMACIE BERGEZ-BEVALOT France 25000

Study participating centre PHARMACIE RODIER CABANIS France 30420

Study participating centre PHARMACIE DODIN-MOTTE France 95290

Study participating centre PHARMACIE DECLOITRE France 33000

PHARMACIE MILLERET-VERNAY France 21250

Study participating centre PHARMACIE DOUCET France 45260

Study participating centre PHARMACIE BEL France 31340

Study participating centre PHARMACIE GIRARD-PLANTE-VIEITEZ France 31660

Study participating centre PHARMACIE LHOYER France 60160

Study participating centre PHARMACIE SENEZ VANGHELUE France 60840

Study participating centre PHARMACIE COUFFIGNAL-BONNY France 94370

PHARMACIE AATEF-VINAY France 26000

Study participating centre PHARMACIE HENRY France 18120

Study participating centre PHARMACIE EDUS France 90170

Study participating centre PHARMACIE BIZON France 49280

Study participating centre PHARMACIE CHARTIER SEBASTIEN France 62660

Study participating centre PHARMACIE LECUGY-VINCENT France 45420

Study participating centre PHARMACIE NOLL France 67280

PHARMACIE BLAISE-GRASMICK France 54220

Study participating centre PHARMACIE BERA France 38114

Study participating centre PHARMACIE COGNARD-LOURADOUR France 87920

Study participating centre PHARMACIE GUILLEBOT-VERGARA France 31160

Study participating centre PHARMACIE DERAM France 62220

Study participating centre PHARMACIE DESERICOURT-PEREZ France 13100

Study participating centre PHARMACIE LOUBRIEU France 49240

PHARMACIE KARAYAN France

60700

Study participating centre PHARMACIE GUILLEBOT-VERGARA France 31160

Study participating centre PHARMACIE DODIN-MOTTE France 95290

Study participating centre PHARMACIE LE BAIL France 95610

Study participating centre PHARMACIE GIANNECCHINI France 13124

Study participating centre PHARMACIE VIVIEN-MINIGHETTI France 13200

Study participating centre PHARMACIE BERA France 38114

PHARMACIE MAGNIEN France 21240

Study participating centre PHARMACIE FABERT France 23350

Study participating centre PHARMACIE MAGNIEN France 21140

Study participating centre PHARMACIE PENNE-LESPIAU France 40230

Study participating centre PHARMACIE DERAM France 62220

Study participating centre PHARMACIE VIVIEN-MINIGUETTI France 13200

Study participating centre PHARMACIE HAMON-PALLU France 56800

PHARMACIE OSTER-CHILD France 67400

Study participating centre PHARMACIE LAFORTUNE France 91390

Study participating centre PHARMACIE DESACHY-DAVERAT France 40360

Study participating centre PHARMACIE TIVOLLIER-GOBILLOT France 51000

Study participating centre PHARMACIE VIVIEN-MINIGHETTI France 13200

Study participating centre PHARMACIE FACQ France 60160

Study participating centre PHARMACIE MALLIS France 62440

PHARMACIE BROUSSEAU France 44100

Study participating centre PHARMACIE OSTER-HILD France 67400

Study participating centre PHARMACIE GABRIELLNI-DURAND-BRESSAC France 13012

Study participating centre PHARMACIE POTHELUNE France 72190

Study participating centre PHARMACIE PERONNE-DETRIN France 80000

Study participating centre PHARMACIE FRANCK France 93220

Study participating centre PHARMACIE LEBAIL France 95610

PHARMACIE AUCLAIRE France 45390

Study participating centre PHARMACIE MATHEVET France 85250

Study participating centre PHARMACIE TROUILLOT-MAURIN-FAURY-VAZQUEZ France 33190

Study participating centre PHARMACIE MOUTIER-DUMAS France 87130

Study participating centre PHARMACIE RETAILLEAU France 85600

Study participating centre PHARMACIE LEFEBRVRE-RICQUEBOURG France 95710

Study participating centre PHARMACIE POLETTI-REPELLIN France 73200

PHARMACIE PERONNE-DETRIN France 80000

Study participating centre PHARMACIE BONCHRISTIANI-ANDREANI France 13013

Study participating centre PHARMACIE HAMON-PALLU France 56800

Study participating centre PHARMACIE MEUNIER France 42100

Study participating centre PHARMACIE PENICAUT-BECHADE France 87800

Study participating centre PHARMACIE CAMY France 34070

Study participating centre PHARMACIE LE BAIL France 95610

PHARMACIE AGRA France 49510

Study participating centre PHARMACIE SICARD France 51000

Study participating centre PHARMACIE POTHELUNE France 72190

Study participating centre PHARMACIE LECUGY-VINCENT France 45420

Study participating centre PHARMACIE MIR-RABILLER France 65170

Study participating centre PHARMACIE CHAU France 92160

Study participating centre PHARMACIE MALLIS France 62440

PHARMACIE CHIEP

France 91160

Study participating centre PHARMACIE LAIR-MARTIN-LONGUESSERRE France 31260

Study participating centre PHARMACIE GIMENO-BUSSON France 41210

Study participating centre PHARMACIE OSTER-HILD France 67400

Study participating centre PHARMACIE DE GRAEVE-MASSIP France 31600

Study participating centre PHARMACIE COUTINHO DE ALMEIDA France 85000

Study participating centre PHARMACIE FAURY France 17610

PHARMACIE BORDAT France 84300

Study participating centre PHARMACIE LEPINE France 87220

Study participating centre PHARMACIE ROUSSEAU France 45250

Study participating centre PHARMACIE LAFFLY France 1000

Study participating centre PHARMACIE CORGNE France 81800

Study participating centre PHARMACIE COUTINHO DE ALMEIDA France 85000

Study participating centre PHARMACIE STAHL France 88290

PHARMACIE BAFFOUX - ROUET France 86000

Study participating centre PHARMACIE LE BAIL France 95610

Study participating centre PHARMACIE BOUCHARD France 78610

Study participating centre PHARMACIE VAURY France 91670

Study participating centre PHARMACIE BORDAT France 84300

Study participating centre PHARMACIE MONTAGNY-WELLHOFF France 92270

Study participating centre PHARMACIE VAURY France 91670

PHARMACIE BAUDIN-CIMETIERE France 71520

Study participating centre PHARMACIE LAFORTUNE France 91390

Study participating centre PHARMACIE THOMAS France 79380

Study participating centre PHARMACIE LEFEBVRE-RICQUEBOURG France 95710

Study participating centre PHARMACIE SCHREVEL France 94400

Study participating centre PHARMACIE GERMES - CANEPA France 35300

Study participating centre PHARMACIE THOUVEREY France 71500

PHARMACIE LOUBRIEU France 49240

Study participating centre PHARMACIE OSTER-HILD France 67400

Study participating centre PHARMACIE ENJALBERT - LAMASSIAUDE France 82130

Study participating centre PHARMACIE LEFEBVRE-RICQUEBOURG France 95710

Study participating centre PHARMACIE SAHUGUET France 54110

Study participating centre PHARMACIE COGNARD - LOURADOUR France 87920

Study participating centre PHARMACIE HENRY France 18120

PHARMACIE HAMON - PALLU France 56800

Study participating centre PHARMACIE SEGUIN France 69290

Study participating centre PHARMACIE BONNIN - JOUANNIN France 23320

Study participating centre PHARMACIE LAIR -MARTIN -LONGUESSERRE France 31260

Study participating centre PHARMACIE SOL-GIRAL France 43110

Study participating centre PHARMACIE DECLOITRE France 3300

Study participating centre PHARMACIE COGNARD - LOURADOUR France 87920

PHARMACIE BARBE - LECLERCQ France 89110

Study participating centre PHARMACIE VIVIEN - MINIGHETTI France 13200

Study participating centre PHARMACIE TIVOLLIER - GOBILLOT France 51000

Study participating centre PHARMACIE LEYENDECKER France 67130

Study participating centre PHARMACIE SEGUIN France 69290

Study participating centre PHARMACIE BOUREL - EQUINET France 80090

Study participating centre PHARMACIE DOUCET France 45260

PHARMACIE LESOIF-GRIMAULT France 53500

Study participating centre PHARMACIE BEGLIA JOEL France 13200

Study participating centre PHARMACIE MOUSSLY France 51230

Study participating centre PHARMACIE BOURDY-DUBOIS-CHANEL France 58640

Study participating centre PHARMACIE VIVIEN - MINIGHETTI France 13200

Study participating centre PHARMACIE HENRY France 18120

Study participating centre PHARMACIE COHARD France 86540

PHARMACIE LESOIF-GRIMAULT France 53500

Sponsor information

Organisation Observia

Sponsor details Pépinière Paris Santé Cochin 29, Rue du Faubourg Saint Jacques Paris France 75014 +33 (0)1 81 80 24 50 laura.romengas@observia-group.com

Sponsor type Research organisation

Organisation MSD France

Sponsor details 34 Avenue Léonard de Vinci Courbevoie France 92400

Sponsor type Industry

Funder(s)

Funder type Industry

Funder Name Merck

Alternative Name(s)

Merck & Co., Inc., Merck & Co.

Funding Body Type Government organisation

Funding Body Subtype For-profit companies (industry)

Location United States of America

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact reviewed journal.

Intention to publish date

31/12/2017

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Laura Romengas (laura.romengas@observia-group.com).

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2019	01/05/2020	Yes	No